Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. Its marketed products include Xywav for cataplexy or excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia; Epidiolex for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex; Rylaze and Enrylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Zepzelca for metastatic small cell lung cancer progressing on or after platinum-based chemotherapy; Ziihera for HER2-positive biliary tract cancers; Modeyso for diffuse midline glioma with an H3 K27M mutation; and Defitelio for severe veno-occlusive disease. The company also develops Zanidatamab in Phase 3 trials for HER2-positive gastroesophageal adenocarcinoma and biliary tract cancers, Dordaviprone for H3 K27M-mutant diffuse glioma, and Vyxeos for newly diagnosed therapy-related acute myeloid leukemia. Additional programs include Zanidatamab for neoadjuvant and adjuvant breast cancer; Vyxeos for high-risk MDS, newly diagnosed untreated high-risk AML, and de novo intermediate or adverse risk AML stratified by genomics; JZP3507 for pheochromocytoma and paraganglioma in Phase 2; and JZP815 for Raf and Ras mutant tumors, JZP898 for the IFN INDUKIN molecule in solid tumors, and JZP047 for absence epilepsy in Phase 1. Jazz Pharmaceuticals plc has collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc., and AbCellera Biologics Inc. Founded in 2003, the company is headquartered in Dublin, Ireland.
Jazz beats Q2, raises guidance, and buys Actio Biosciences
▲
Q2 revenue beat and raised full-year guidance Jazz reported Q2 revenue of $1.21 billion, beating estimates and up 15.5% from a year ago. Management raised full-year revenue guidance to $4.68 billion, well above Wall Street's expectation. Adjusted earnings per share missed, but the strong sales outlook and improved operating margin pushed shares up 2.5%.
This is the biggest new event, directly showing stronger sales and a brighter outlook that lifts the stock.
▲
Acquisition of Actio Biosciences for $820 million upfront Jazz agreed to buy privately held Actio Biosciences for $820 million upfront plus up to $500 million in milestones. This adds new rare-disease drug programs to Jazz's pipeline. Investors often see bolt-on deals as a sign of confidence and future growth, which supports the stock price.
This is a fresh, concrete move that expands Jazz's pipeline and signals growth, directly affecting the investment case.
▲
AbCellera cancer antibody collaboration Jazz signed a deal with AbCellera to discover new cancer antibodies for gastrointestinal and other solid tumors. Jazz paid $56 million upfront and could pay up to $792 million in milestones. This expands Jazz's oncology pipeline, a positive for long-term growth, though any revenue is years away.
It is a new partnership that broadens Jazz's cancer research, supporting the stock's long-term potential.
▼
Zepzelca fails second-line lung cancer trial Jazz's drug Zepzelca failed a phase 3 trial in second-line small-cell lung cancer, missing the main goal of helping patients live longer. However, Jazz's focus has already shifted to Zepzelca's first-line use, which is approved and growing fast. The failure is a setback but not a major financial blow.
This is a new negative event, but its limited impact due to the first-line shift makes it a balanced point.
Q3 2026
▲3▼1
Jazz beats Q2, raises guidance, and buys Actio Biosciences
▲
Q2 revenue beat and raised full-year guidance Jazz reported Q2 revenue of $1.21 billion, beating estimates and up 15.5% from a year ago. Management raised full-year revenue guidance to $4.68 billion, well above Wall Street's expectation. Adjusted earnings per share missed, but the strong sales outlook and improved operating margin pushed shares up 2.5%.
This is the biggest new event, directly showing stronger sales and a brighter outlook that lifts the stock.
▲
Acquisition of Actio Biosciences for $820 million upfront Jazz agreed to buy privately held Actio Biosciences for $820 million upfront plus up to $500 million in milestones. This adds new rare-disease drug programs to Jazz's pipeline. Investors often see bolt-on deals as a sign of confidence and future growth, which supports the stock price.
This is a fresh, concrete move that expands Jazz's pipeline and signals growth, directly affecting the investment case.
▲
AbCellera cancer antibody collaboration Jazz signed a deal with AbCellera to discover new cancer antibodies for gastrointestinal and other solid tumors. Jazz paid $56 million upfront and could pay up to $792 million in milestones. This expands Jazz's oncology pipeline, a positive for long-term growth, though any revenue is years away.
It is a new partnership that broadens Jazz's cancer research, supporting the stock's long-term potential.
▼
Zepzelca fails second-line lung cancer trial Jazz's drug Zepzelca failed a phase 3 trial in second-line small-cell lung cancer, missing the main goal of helping patients live longer. However, Jazz's focus has already shifted to Zepzelca's first-line use, which is approved and growing fast. The failure is a setback but not a major financial blow.
This is a new negative event, but its limited impact due to the first-line shift makes it a balanced point.
News & notes movingJAZZ
United StatesUnited Kingdom
Biotech & Genomic Medicine▼impact 4
Amgen and AstraZeneca Lung Cancer Combo Meets Survival Goal in Phase III Study
Amgen and AstraZeneca announced positive results from a phase III study of Imdelltra, or tarlatamab, in combination with AstraZeneca's Imfinzi, or durvalumab, in certain patients with extensive-stage small-cell lung cancer. The trial, called DeLLphi-305, tested the combination against Imfinzi alone as a first-line maintenance treatment for patients whose cancer had not progressed after induction with Imfinzi plus platinum chemotherapy and etoposide. The study met its primary endpoint of overall survival and a key secondary endpoint of progression-free survival, though neither company provided numerical data and both said no new safety concerns were identified. DeLLphi-305 is sponsored by Amgen, with partial funding and Imfinzi supplied by AstraZeneca. AstraZeneca estimates that roughly 195,000 people globally will be treated for extensive-stage small-cell lung cancer in 2026, and the companies say small-cell lung cancer accounts for about 15% of lung cancers, with about two-thirds of those patients diagnosed with the extensive-stage form. If approved, the Imfinzi-Imdelltra combination would enter a first-line maintenance market where the FDA in October 2025 approved Jazz Pharmaceuticals' Zepzelca, or lurbinectedin, with Roche's Tecentriq, or atezolizumab, based on the IMforte study, which showed a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death versus Tecentriq alone. Imdelltra, a bispecific T-cell engager approved in 2024 for second-line extensive-stage small-cell lung cancer, posted global sales of $546 million in the first half of 2026, up from $215 million a year earlier, while Imfinzi's first-half 2026 revenues rose 31% year over year to $3.55 billion.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
AMGN · Technology · Positive Amgen-sponsored phase III DeLLphi-305 of Imdelltra plus Imfinzi met overall survival and progression-free survival endpoints in extensive-stage small-cell lung cancer.
AZN.LSE · Technology · Positive AstraZeneca's Imfinzi combined with Amgen's Imdelltra met primary and key secondary endpoints in the DeLLphi-305 phase III trial.
JAZZ · Competition · Negative Jazz's Zepzelca-Tecentriq first-line maintenance combo faces a new rival if the Imfinzi-Imdelltra combination is approved.
ROP.SW · Competition · Negative Roche's Tecentriq, used with Jazz's Zepzelca in first-line maintenance, would face competition from the Imfinzi-Imdelltra combination.
Jazz's Ziihera Shows Survival Benefit Over Trastuzumab in Phase 3 Trial
Jazz Pharmaceuticals reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial, with the hazard ratio improving from the first interim analysis. The global, open-label study randomized 914 patients across more than 30 countries, comparing Ziihera plus chemotherapy, Ziihera plus tislelizumab and chemotherapy, and trastuzumab plus chemotherapy as first-line treatments for HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma, with overall survival and progression-free survival as dual primary endpoints. The result strengthens the argument that Ziihera, a bispecific HER2-directed antibody, can displace trastuzumab as the HER2 backbone in this setting, though commercial implications depend on the size, durability, and consistency of the survival benefit. The FDA approved Ziihera plus chemotherapy for first-line treatment of HER2-positive IHC 3+ disease on August 25, 2026, and also approved Ziihera plus tislelizumab and chemotherapy for IHC 3+ or IHC 2+/ISH+ disease, providing an immediate commercial pathway. Jazz has not disclosed the updated median overall survival, hazard ratio, confidence interval, survival curves, or subgroup results, and safety concerns include boxed warnings for diarrhea and embryo-fetal toxicity, with diarrhea reported in 81% of 395 patients receiving Ziihera plus chemotherapy, including Grade 3 events in 20% and Grade 4 events in 1.3%. Hedge fund holdings in Jazz fell to 46 funds at the end of 2Q2026 from 48 funds three months earlier, according to Insider Monkey's database.
Jazz Pharmaceuticals Rises on Updated OS Results from Gastric Cancer Study
Jazz Pharmaceuticals announced updated overall survival results from the phase III HERIZON-GEA-01 study, showing that its drug Ziihera, combined with chemotherapy, significantly improved survival in first-line HER2-positive gastroesophageal adenocarcinoma compared to standard care. The second interim analysis also demonstrated a statistically significant and durable benefit for the three-drug regimen of Ziihera, Tevimbra, and chemotherapy. These results follow the FDA's recent label expansion of Ziihera for this indication, which significantly broadens its market opportunity beyond its existing use in biliary tract cancer. Shares of Jazz rose 2.5% on the news and have gained 47.5% year-to-date, outperforming the industry's 9.7% increase.
Jazz Pharmaceuticals prices upsized $1.1B debt offering
Jazz Pharmaceuticals has priced an upsized private offering of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, up from the previously announced $1 billion. The notes will accrue interest semiannually at 1.875% per year, with payments beginning March 15, 2027, and will mature on September 15, 2032, unless earlier exchanged, redeemed, or repurchased. The company has also granted initial purchasers an option to buy up to an additional $150 million in notes within 13 days from the issue date. The sale is expected to close on August 31, 2026, and the stock closed down 4% on Wednesday.
Roche gets FDA approval for HER2 companion diagnostics in gastroesophageal cancer
Roche announced that the FDA has approved expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail tests as companion diagnostics to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma, including gastric, gastroesophageal junction, and esophageal adenocarcinoma, who may be eligible for treatment with Jazz Pharmaceuticals' ZIIHERA. This approval broadens the patient population eligible for HER2-targeted therapy, as previously no tests were approved to determine HER2 status in esophageal cancer. The tests, already widely used in breast and gastric cancers, are now part of Roche's comprehensive HER2 diagnostic portfolio, supporting personalized treatment approaches for this hard-to-treat disease.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
ROP.SW · Technology · Positive FDA approves expanded use of Roche's HER2 companion diagnostics, broadening its diagnostic portfolio.
JAZZ · Demand · Positive Approval expands use of companion diagnostics that identify patients eligible for Jazz's ZIIHERA, potentially increasing its market.
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab
Zymeworks shares climbed nearly 4.0% in pre-market trading as investors positioned themselves ahead of an important U.S. regulatory decision on zanidatamab, expected the following day. The FDA's PDUFA target action date for zanidatamab, a bispecific HER2-targeting antibody developed alongside Jazz Pharmaceuticals, is August 25, 2026, with the regulator reviewing the treatment for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Approval would immediately trigger a $250 million U.S. regulatory milestone payment, with up to an additional $190 million possible through regulatory milestones in other markets. Citi placed the stock on an upside 90-day catalyst watch earlier in August, while Truist and Wells Fargo have increased their price targets ahead of the PDUFA date. Zymeworks is also pursuing a roughly $929 million all-cash acquisition of Theravance Biopharma, expected to close in the second half of 2026, which would add commercial cash flows from the COPD treatment YUPELRI.
Workday, Diversified Energy, Aurora Cannabis lead week's key deals
Several major acquisition deals were reported across sectors this week. Workday soared 19% on a report that private equity firm Silver Lake is in talks to buy the software company. Diversified Energy is in advanced talks to acquire Elliott Investment Management-backed oil and gas company Birch Resources for more than $1.7 billion in cash. EQT Infrastructure offered to buy Cleanaway Waste Management in a deal that values the Australian listed firm at about A$6.9 billion, or $4.9 billion. H.B. Fuller said it received an unsolicited proposal from Ancora Holdings to buy its building adhesives solutions business for $1.1 billion to $1.2 billion in cash. Aurora Cannabis soared 21% after Curaleaf Holdings said it plans to make a $4 per share takeover bid, with Curaleaf rising 6.7%. H&R Real Estate Investment Trust agreed to be acquired by GO Residential Real Estate Investment Trust and a consortium including Blackstone, Crestpoint, PSP Investments and a company controlled by members of the family of H&R CEO Tom Hofstedter in a deal valued at about C$6.7 billion, including assumed debt. Israeli AI startup Decart is in advanced talks to be sold to a major tech firm for $6 billion to $7 billion. Jazz Pharmaceuticals announced it will acquire privately held Actio Biosciences for $820 million upfront and up to $500 million in potential milestones.
AbCellera Reports Q2 2026 Net Loss Widens to $55 Million as Revenue Falls to $4 Million
AbCellera Biologics reported a net loss of roughly $55 million for the second quarter of 2026, up from a $35 million loss a year earlier, while total revenue dropped to approximately $4 million from $17 million. The company completed enrollment for the phase 2 study of ABCL-635 in treating hot flashes ahead of schedule, with top-line data expected soon, and secured new T-cell engager collaborations with Vertex and Jazz Pharmaceuticals that added over $110 million in upfront cash. AbCellera maintains a strong liquidity position with over $565 million in cash and equivalents plus roughly $110 million in committed government funding, providing a runway of at least three years. Research and development expenses increased by about $7 million year-over-year, and the company missed its internal goal of moving another program into IND-enabling activities in the first half of 2026. The upcoming phase 2 data for ABCL-635 carries scientific risks, including the unresolved question of whether blocking NK3R in the pre-optic nucleus is necessary for efficacy, and the company acknowledged a pronounced placebo response in similar trials.
Jazz Pharmaceuticals beats Q2 revenue estimates and raises full-year guidance
Jazz Pharmaceuticals reported second-quarter 2026 revenue of $1.21 billion, exceeding analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion at the midpoint, up from $4.38 billion and 3.6% above Wall Street expectations. Adjusted earnings per share came in at $5.71, missing the consensus estimate of $6.18 by 7.5%. Adjusted operating margin improved to 20.5% from negative 65.6% in the same quarter last year. Shares rose 2.5% to $257.97 following the announcement.
Palantir, Vertex, and Diamondback lead after-hours earnings reports for August 3, 2026
A slate of major companies including Palantir Technologies, Vertex Pharmaceuticals, and Diamondback Energy are set to report quarterly earnings after the market closes on August 3, 2026. Palantir is expected to post earnings per share of $0.28, a 115.38% jump from the same quarter last year, while Vertex's consensus stands at $4.30, up 7.50%. Diamondback Energy's forecast of $6.08 per share represents a 127.72% surge, though it missed estimates in the fourth quarter of 2025. Other notable reports include ONEOK with a consensus of $1.39, ON Semiconductor at $0.72, and SBA Communications at $2.76, which would mark a 12.93% decline year-over-year. Sterling Infrastructure is projected to deliver $5.00 per share, a 96.08% increase, and Jazz Pharmaceuticals is expected to swing to $5.06 per share after a large miss in the prior-year quarter.
Biotech Stocks IKT, HALO, JAZZ, CORT, LQDA Hit 52-Week Highs
Several biotech stocks reached 52-week highs on July 24, 2026, driven by upcoming quarterly reports and regulatory milestones. Inhibikase Therapeutics hit $2.53 after its lead candidate IKT-001 received FDA Orphan Drug designation for pulmonary arterial hypertension, with a global Phase 3 trial underway. Jazz Pharmaceuticals reached $256.75, supported by 19% first-quarter revenue growth to $1.1 billion and progress with Zanidatamab in breast cancer studies. Halozyme Therapeutics climbed to $82.99 following a 42% year-over-year revenue increase to $376 million in the first quarter and full-year guidance of $1.71 billion to $1.81 billion. Corcept Therapeutics touched $97.63, with first-quarter revenue rising to $164 million from $157 million a year earlier, ahead of its July 29 earnings report. Liquidia Corporation hit $91.10, buoyed by $130 million in first-quarter YUTREPIA sales and a net income of $52 million.
Jazz Pharmaceuticals may extend earnings beat streak with positive ESP
Jazz Pharmaceuticals has a positive Zacks Earnings ESP of +0.41% and a Zacks Rank #3, a combination that historically produces an earnings beat nearly 70% of the time. The company has beaten estimates in its last two quarters, with an average surprise of 18.03%, including a 35.76% beat last quarter when it reported $6.34 per share versus a $4.67 consensus. Its next earnings report is expected on August 3, 2026.
Jazz Pharmaceuticals refocuses sleep franchise as Axsome files for narcolepsy drug
Jazz Pharmaceuticals is refocusing its sleep-disorder franchise after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi's move from Jazz's portfolio. Jazz shares have returned 119.3% over the past year and 42.3% over five years, with a 9.1% gain in the last month. The stock closed at $247.53, about 6% below the average analyst target, while Simply Wall St estimates a fair value of $257.00, suggesting the stock is slightly undervalued. Expected approvals for dordaviprone in H3 K27M-mutant diffuse glioma and Zepzelca in first-line small cell lung cancer maintenance are seen as key growth drivers, though risks include patent expirations and reliance on a few pipeline launches.
VERAXA Biotech shareholders urged to watch antibody therapeutics sector deals
Strategic licensing agreements and acquisitions in antibody-drug conjugates and T-cell engager therapeutics continue to create significant value for platform companies well before pivotal clinical trials. The Jazz Pharmaceuticals–AbCellera collaboration exemplifies how differentiated antibody technologies can command substantial financial commitments prior to clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two modalities that continue to attract strategic partnerships. Recent transactions demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Competition
Biotech & Genomic Medicine › AI Drug Discovery Technology
VACH · Demand · Positive VERAXA Biotech is positioned as having a platform across ADCs and T-cell engagers, which are attracting strategic partnerships, implying potential demand.
ABCL · Demand · Positive AbCellera's collaboration with Jazz Pharmaceuticals is cited as an example of a strategic licensing deal, indicating demand for its antibody platform.
JAZZ · Demand · Positive Jazz Pharmaceuticals' collaboration with AbCellera is highlighted as a significant strategic partnership, showing demand for differentiated antibody technologies.
Harmony Biosciences is expanding its pipeline beyond its core narcolepsy drug Wakix to build a broader neuroscience franchise. The company is advancing pitolisant into late-stage trials for idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1, while developing gastro-resistant and high-dose formulations to improve tolerability and target fatigue and sleep inertia, with top-line data expected in 2027 and a target action date in 2028. Harmony is also entering orexin-2 receptor agonism with BP1.15205, a once-daily candidate for narcolepsy, and rare epilepsy through EPX-100, which is enrolling in two global Phase III trials for Lennox-Gastaut syndrome and Dravet syndrome. The company faces increasing competition from multiple orexin-2 receptor agonists nearing approval, which could heighten payer scrutiny and pressure differentiation. HRMY carries a Zacks Rank #3 (Hold) with a Value Score of A and a Growth Score of B, but a Momentum Score of D suggests investors may need patience as the market awaits clearer pipeline data.
HRMY · Technology · Positive Pipeline expansion with pitolisant in multiple indications and orexin-2 agonist BP1.15205, with late-stage trials and expected data.
HRMY · Competition · Negative Multiple orexin-2 receptor agonists nearing approval could increase payer scrutiny and pressure differentiation.
JAZZ · Competition · Negative Harmony's pipeline expansion, including orexin-2 agonism, may increase competition for Jazz's narcolepsy franchise.
Jazz Pharmaceuticals expands AbCellera tie-up as Zepzelca trial misses goal
Jazz Pharmaceuticals expanded its collaboration with AbCellera Biologics to develop next-generation T-cell multispecific antibodies for gastrointestinal and other solid tumors. The company also reported that the Phase 3 LAGOON trial of Zepzelca in second-line small cell lung cancer did not meet its primary endpoint. Zepzelca retains its first-line approval based on prior studies, and Jazz is in discussions with the FDA about future steps. Management indicated that current financial guidance is unchanged.
Jazz Pharmaceuticals and AbCellera Partner on Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals and AbCellera Biologics have entered a preclinical research collaboration to discover and develop next-generation T-cell-engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. Under the deal, Jazz will make upfront payments totaling $56 million for the first two discovery programs, with an additional $28 million due upon initiation of a third program within 12 months. For each program Jazz advances, AbCellera is eligible to receive up to $792 million in option fees and milestone payments, plus tiered royalties on future net sales ranging from the mid-single digits to the low double digits. Jazz gains access to AbCellera's antibody discovery platform and T-cell engager technology, while retaining exclusive options to develop and commercialize resulting therapeutic antibodies. The collaboration may expand by up to two additional programs by mutual agreement.
Biotech & Genomic Medicine › AI Drug Discovery ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics Competition
ABCL · Technology · Positive AbCellera's antibody discovery platform and T-cell engager technology are central to the collaboration, with upfront payments and potential milestones up to $792M per program.
JAZZ · Technology · Positive Jazz gains access to AbCellera's platform to develop next-generation T-cell-engaging multispecific antibodies for solid tumors, with exclusive options to commercialize.
USA
